Security key
114082209
Ernexa Therapeutics Inc. - Common Stock (ERNA)
CUSIP: 114082209
Q4 2022 13F Holders as of 31 Dec 2022
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 329,815
- Total 13F value
- $1,192,085
- Share change
- +268,626
- SEC-reported price per share
- $3.22
- Number of holders
- 18
- Value change
- +$995,056
- Number of buys
- 17
- Shares outstanding
- 1,166,181
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2022
Institutions
18
Top holders
10
ERNA full security history
Ownership snapshot
Full 13F holder table
Ernexa Therapeutics Inc. SEC filings
Ernexa Therapeutics Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of ERNA - Ernexa Therapeutics Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
George P. Denny III
Disclosed value leader
George P. Denny III
Comparable rows
0/14
Latest evidence
02 Dec 2022
3/4/5
Highest disclosed value: $1,134,456
14 rows are not safely comparable across share classes.
Showing 1-6 of 14 holder rows.
Quick read
George P. Denny III has the largest disclosed position value at $1.13M.
0 of 14 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens George P. Denny III's linked filing trail.
Disclosed position value
Top 5
George P. Denny III
$1.13M
John D. Halpern
$1.12M
Nicholas J. Singer
$962.3K
Roger Sidhu
$200K
Kevin Damour
$159.2K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 14 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| George P. Denny III |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$1,134,456
457,442 shares
|
— | 02 Dec 2022 |
| John D. Halpern |
3/4/5
10%+ Owner
|
—
mixed-class rows
|
$1,118,891
1,123,006 shares
mixed-class rows
|
— | 02 Dec 2022 |
| Nicholas J. Singer |
3/4/5
Director
|
—
mixed-class rows
|
$962,330
954,608 shares
mixed-class rows
|
— | 02 Dec 2022 |
| Roger Sidhu |
3/4/5
Chief Medical Officer
|
—
mixed-class rows
|
$200,012
80,650 shares
mixed-class rows
|
— | 20 Sep 2022 |
| Kevin Damour |
3/4/5
Chief Scientific Officer
|
—
mixed-class rows
|
$159,248
64,213 shares
mixed-class rows
|
— | 28 Jun 2022 |
| Andrew C. Jackson |
3/4/5
Chief Financial Officer
|
—
class O/S missing
|
—
664,800 shares
|
— | 03 Jun 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2022
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
18
Shares
329,815
Rows available
18
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2022 vs Q3 2022 Across Filers
Q3 2022 holders
0
Q4 2022 holders
18
Holder diff
18
| Investor | Q3 2022 Shares | Q4 2022 Shares | Share Diff | Share Chg % | Q3 2022 value | Q4 2022 value | Value change | Value Chg % |
|---|